Quantifying Energy Intake Changes During Obesity Pharmacotherapy

Overview

Journal Obesity (Silver Spring)

Specialties Endocrinology
Nutritional Sciences
Physiology

Date 2014 Jun 26

PMID 24961931

Citations 12

Authors

Britta Gobel

Arjun Sanghvi

Kevin D Hall

Affiliations

Soon will be listed here.

Abstract

Objective: Despite the fact that most obesity drugs primarily work by reducing metabolizable energy intake, elucidation of the time course of energy intake changes during long-term obesity pharmacotherapy has been prevented by the limitations of self-report methods of measuring energy intake.

Methods: A validated mathematical model of human metabolism was used to provide the first quantification of metabolizable energy intake changes during long-term obesity pharmacotherapy using body weight data from randomized, placebo-controlled trials that evaluated 14 different drugs or drug combinations.

Results: Changes in metabolizable energy intake during obesity pharmacotherapy were reasonably well-described by an exponential pattern comprising three simple parameters, with early large changes in metabolizable energy intake followed by a slow transition to a smaller persistent drug effect.

Conclusions: Repeated body weight measurements along with a mathematical model of human metabolism can be used to quantify changes in metabolizable energy intake during obesity pharmacotherapy. The calculated metabolizable energy intake changes followed an exponential time course, and therefore different drugs can be evaluated and compared using a common mathematical framework.

Citing Articles

Physiology of the weight-loss plateau in response to diet restriction, GLP-1 receptor agonism, and bariatric surgery.

Hall K Obesity (Silver Spring). 2024; 32(6):1163-1168.

PMID: 38644683 PMC: 11132924. DOI: 10.1002/oby.24027.

Energy homeostasis from Lavoisier to control theory.

Geary N Philos Trans R Soc Lond B Biol Sci. 2023; 378(1885):20220201.

PMID: 37482775 PMC: 10363704. DOI: 10.1098/rstb.2022.0201.

Host-diet-gut microbiome interactions influence human energy balance: a randomized clinical trial.

Corbin K, Carnero E, Dirks B, Igudesman D, Yi F, Marcus A Nat Commun. 2023; 14(1):3161.

PMID: 37258525 PMC: 10232526. DOI: 10.1038/s41467-023-38778-x.

Glucagon-like peptide-1/glucagon receptor agonism associates with reduced metabolic adaptation and higher fat oxidation: A randomized trial.

Corbin K, Carnero E, Allerton T, Tillner J, Bock C, Luyet P Obesity (Silver Spring). 2023; 31(2):350-362.

PMID: 36695055 PMC: 9881753. DOI: 10.1002/oby.23633.

Objective versus Self-Reported Energy Intake Changes During Low-Carbohydrate and Low-Fat Diets.

Guo J, Robinson J, Gardner C, Hall K Obesity (Silver Spring). 2019; 27(3):420-426.

PMID: 30672127 PMC: 6392435. DOI: 10.1002/oby.22389.

References

Winkler J . The fundamental flaw in obesity research. Obes Rev. 2005; 6(3):199-202. DOI: 10.1111/j.1467-789X.2005.00186.x. View

Gadde K, Allison D, Ryan D, Peterson C, Troupin B, Schwiers M . Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011; 377(9774):1341-52. DOI: 10.1016/S0140-6736(11)60205-5. View

Bray G . Medications for weight reduction. Endocrinol Metab Clin North Am. 2008; 37(4):923-42. DOI: 10.1016/j.ecl.2008.08.004. View

Hollander P, Gupta A, Plodkowski R, Greenway F, Bays H, Burns C . Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013; 36(12):4022-9. PMC: 3836105. DOI: 10.2337/dc13-0234. View

Weintraub M, SUNDARESAN P, Madan M, Schuster B, Balder A, Lasagna L . Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther. 1992; 51(5):586-94. DOI: 10.1038/clpt.1992.69. View

Torgerson J, Hauptman J, Boldrin M, Sjostrom L . XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2003; 27(1):155-61. DOI: 10.2337/diacare.27.1.155. View

Schoeller D, Thomas D, Archer E, Heymsfield S, Blair S, Goran M . Self-report-based estimates of energy intake offer an inadequate basis for scientific conclusions. Am J Clin Nutr. 2013; 97(6):1413-5. PMC: 6546220. DOI: 10.3945/ajcn.113.062125. View

Martin C, Das S, Lindblad L, Racette S, McCrory M, Weiss E . Effect of calorie restriction on the free-living physical activity levels of nonobese humans: results of three randomized trials. J Appl Physiol (1985). 2011; 110(4):956-63. PMC: 3075130. DOI: 10.1152/japplphysiol.00846.2009. View

Hall K, Heymsfield S, Kemnitz J, Klein S, Schoeller D, Speakman J . Energy balance and its components: implications for body weight regulation. Am J Clin Nutr. 2012; 95(4):989-94. PMC: 3302369. DOI: 10.3945/ajcn.112.036350. View

10.

Pfohl M, Luft D, Blomberg I, Schmulling R . Long-term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine. Int J Obes Relat Metab Disord. 1994; 18(6):391-5. View

11.

Suplicy H, Boguszewski C, dos Santos C, do Desterro de Figueiredo M, Cunha D, Radominski R . A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. Int J Obes (Lond). 2013; 38(8):1097-103. DOI: 10.1038/ijo.2013.225. View

12.

Schoeller D . How accurate is self-reported dietary energy intake?. Nutr Rev. 1990; 48(10):373-9. DOI: 10.1111/j.1753-4887.1990.tb02882.x. View

13.

James W, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A . Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010; 363(10):905-17. DOI: 10.1056/NEJMoa1003114. View

14.

Hauptman J, Lucas C, Boldrin M, Collins H, Segal K . Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000; 9(2):160-7. DOI: 10.1001/archfami.9.2.160. View

15.

Hall K, Sacks G, Chandramohan D, Chow C, Wang Y, Gortmaker S . Quantification of the effect of energy imbalance on bodyweight. Lancet. 2011; 378(9793):826-37. PMC: 3880593. DOI: 10.1016/S0140-6736(11)60812-X. View

16.

Garvey W, Ryan D, Look M, Gadde K, Allison D, Peterson C . Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2011; 95(2):297-308. PMC: 3260065. DOI: 10.3945/ajcn.111.024927. View

17.

Scheen A, Finer N, Hollander P, Jensen M, Van Gaal L . Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 2006; 368(9548):1660-72. DOI: 10.1016/S0140-6736(06)69571-8. View

18.

Allison D, Gadde K, Garvey W, Peterson C, Schwiers M, Najarian T . Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2011; 20(2):330-42. PMC: 3270297. DOI: 10.1038/oby.2011.330. View

19.

DeFronzo R, Ratner R, Han J, Kim D, Fineman M, Baron A . Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005; 28(5):1092-100. DOI: 10.2337/diacare.28.5.1092. View

20.

Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean M . Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2011; 36(6):843-54. PMC: 3374073. DOI: 10.1038/ijo.2011.158. View